11 news items
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
11 Jun 24
Important Safety Information. Forward-looking Statements This press release contains forward-looking statements
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
. Setmelanotide was well tolerated with no new safety concerns.Dr. Roth presented the design of Rhythm's first-in-human Phase 1 trial of once
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
RYTM
3 Jun 24
reactions in Europe. Please see the full Prescribing Information for additional Important Safety Information
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
.] By reporting side effects, you can help provide more information on the safety of this medicine. Please see the Summary
Rhythm Pharmaceuticals Presents Data From Phase 3 Pediatrics Trial At Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
""Efficacy in Weight Reduction and Safety in Pediatric Age Groups With Rare Melanocortin-4 Receptor Pathway–Related Obesity Treated With a Therapy for 12 Months"
3vpwsp
RYTM
6 May 24
""Efficacy in Weight Reduction and Safety in Pediatric Age Groups With Rare Melanocortin-4 Receptor Pathway–Related Obesity
a094t9ul
RYTM
29 Apr 24
, and no new safety concerns were observed during the long-term extension trial.In January 2024, Rhythm announced the completion of screening
hze959g5h8legqnlhmusg8xio3km8yltczgdevvnpvx4pkhb4mkvetnyi71
RYTM
29 Apr 24
, no AEs that led to study discontinuation during the trial, and no new safety concerns were observed during the long-term extension trial
ca3xni73ir jcenkb2yz3nd3qydq3
RYTM
24 Apr 24
adverse reactions in Europe. Please see the full Prescribing Information for additional Important Safety Information
r7ew8thoj33qb6qr24u0nwjn3tz h2ev1u553zz08hlr5s4aroc
RYTM
16 Apr 24
on reporting suspected adverse reactions in Europe. Please see the full Prescribing Information for additional Important Safety
jke3o5s2vrbcuwo24531vkvzyx4wayxl p4zch
RYTM
25 Mar 24
- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential
- Prev
- 1
- Next